Skip to main content

Advertisement

Log in

MAFLD: perceived stigma—a single-center Mexican patient survey

  • Letter to the Editor
  • Published:
Hepatology International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Data availability

Due to privacy and ethical concerns, the data can't be made available.

References

  1. Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202–209. https://doi.org/10.1016/j.jhep.2020.03.039

    Article  PubMed  Google Scholar 

  2. Méndez-Sánchez N, Bugianesi E, Gish RG, et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7(5):388–390

    Article  PubMed  Google Scholar 

  3. Mendez-Sanchez N, Arrese M, Gadano A, et al. The Latin American association for the study of the liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol. 2021;6(1):65–72. https://doi.org/10.1016/S2468-1253(20)30340-X

    Article  PubMed  Google Scholar 

  4. Singh SP, Anirvan P, Reddy KR, et al. Non-alcoholic fatty liver disease: Not time for an obituary just yet! J Hepatol. 2021;74(4):972–974. https://doi.org/10.1016/j.jhep.2020.10.015

    Article  PubMed  Google Scholar 

  5. Younossi ZM, Rinella ME, Sanyal AJ, et al. From NAFLD to MAFLD: implications of a premature change in terminology. Hepatology. 2021;73(3):1194–1198. https://doi.org/10.1002/hep.31420

    Article  PubMed  Google Scholar 

  6. Liang Y, Chen H, Liu Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107(1):88–97

    Article  PubMed  Google Scholar 

  7. Tsutsumi T, Eslam M, Kawaguchi T, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51(11):1115–1128. https://doi.org/10.1111/HEPR.13685

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

None.

Author information

Authors and Affiliations

Authors

Contributions

NM-S: conceptualization, manuscript design, data collection, critical revision, supervision; SCP: manuscript writing, analysis and critical revision. EF: data collection, JDF: data collection, JAPR: data collection.

Corresponding author

Correspondence to Nahum Méndez-Sánchez.

Ethics declarations

Conflict of interest

Nahum Méndez-Sánchez, Shreya C. Pal, Eduardo Fassio, Javier Díaz Ferrer, Jorge Alberto Prado Robles declare no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 61 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Méndez-Sánchez, N., Pal, S.C., Fassio, E. et al. MAFLD: perceived stigma—a single-center Mexican patient survey. Hepatol Int 17, 507–508 (2023). https://doi.org/10.1007/s12072-022-10448-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12072-022-10448-y

Navigation